Caribbean International Holdings (CIHN), Announces Site of 2nd International Treatment Facility; Facility is Approved for Ste...
12 5월 2014 - 8:00PM
Both the Protocols and Procedures of therapy
center inside San Javier Hospital, Guadalajara, are certified by
COFEPRIS (Comisión Federal Para la Protección de los Riesgos
Sanitarios).
Caribbean International Holdings (Pink
Sheets:CIHN) through its subsidiary, Regenerative BioScience, Inc.,
("RBS") previously announced on May 7, 2014, that it was opening
new treatment locations in Guadalajara, Mexico, and Cabo St Lucas;
In an update today, it was announced that the location in
Guadalajara was the prestigious San Javier Hospital - Guadalajara.
This will be the Company's second location that will offer stem
cell therapies, in addition to its facilities in the Dominican
Republic.
The hospital houses some of the most accomplished
researchers/therapists in the stem cell field.
The Company plans to add other locations for its stem cell
therapies/services, in order to give the patients more geographic
options to choose from.
Dr. Gonzalez stated: "In a quest to offer patients better
services and options, Regenerative BioScience is identifying key
locations that patients can travel to and obtain excellent stem
cell therapy care. One of those locations we have established lies
in the beautiful, historical city of Guadalajara, Mexico. We are
finalizing negotiations with the private state of the art Hospital
San Javier in Guadalajara, Mexico."
(http://www.sanjavier.com.mx/en/)
Dr. Gonzalez went on to say: "Most importantly, the Hospital San
Javier is approved for stem cell therapies by the FDA equivalent in
Mexico, Comisión Federal Para la Protección de los Riesgos
Sanitarios (COFEPRIS). We are finalizing our medical staff, which
will bring you the patient quality, caring and excellent service in
a secure and ideal setting."
Steven Swank, Chairman and CEO of Caribbean International
Holdings, stated, "We are finalizing our medical staff, which will
bring our patients a superior level of quality, caring and
excellent service in a secure and ideal setting as part of our goal
to make our stem cell therapies a comfortable experience. We also
want to make sure that our patients have options for their therapy.
This location in Guadalajara is ideal and it's a great city to
visit following their therapy. We will soon be naming our medical
director for this facility, which will assure that our patients
obtain excellent quality care, but we are not done. Regenerative
Biosciences will soon add other locations for stem cell therapy in
order to give the patient even more geographic options to choose
from."
About The Company:
Caribbean International Holdings, Inc. is a holding company for
Regenerative BioScience, Inc. ("RBSI"). The Company subsidiary RBSI
is focused on helping individuals to protect and ensure their
future quality of life through Adult Stem Cell Incubation and the
practice of regenerative medicine in the United States and the
Dominican Republic.
RBSI's mission is not only to allow patients to store their Stem
Cells for future use, but also perform patient funded stem cell
therapies for degenerative diseases such as MS, Arthritis,
Degenerative Heart Diseases, Diabetes and a host of experimental
therapies in the brain trauma disease sector including CTE. The
goal is to become a global leader in establishing protocols that
can be patented and utilized to heal patients around the
world.
Adult stem cells work as the repairmen of the body by
replenishing and regenerating damaged tissues and cells. Certain
conditions have shown marked improvement when treated with adult
stem cells taken from the patient's own body. Regenerative
BioScience is a revolution in healthcare using a patient's own
adult stem cells.
For more information go to:
http://www.regenerativebioscience.com/index.html
About: Rafael Gonzalez, Ph.D.
Dr. Gonzalez has expertise in degenerative disorders involving
the spinal cord and has extensive experience in stem cell culture
and biology from human embryonic, pre-natal and adult sources.
Prior to joining DaVinci Biosciences, Dr. Gonzalez served as a
Research Scientist at PrimeGen Biotech where he was responsible for
the design and execution of experiments involving adult (bone
marrow, menstrual blood, adipose) and pre-natal stem cells (neural,
bone marrow, liver, gonadal) for potential clinical application.
Dr. Gonzalez was also responsible for developing PrimeGen's
pre-clinical stem cell/spinal cord injury model.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed
in this press release are forward looking and made pursuant to the
Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. "Forward-looking statements" describe future
expectations, plans, results, or strategies and are generally
preceded by words such as "future," "plan" or "planned," "expects,"
or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond the company's control that may cause actual
results to differ materially from stated expectations. These risk
factors include, among others, limited operating history,
difficulty in developing, exploiting and protecting proprietary
technologies, intense competition and additional risks factors as
discussed in reports filed by the company with the Securities and
Exchange Commission, which are available on at
http://www.sec.gov.
CONTACT: Investor Contact:
BioScience
(941) 924-9400
BioStem Technologies (PK) (USOTC:BSEM)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
BioStem Technologies (PK) (USOTC:BSEM)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
